Shares of NovoCure (NVCR 0.43%) are edging higher on Thursday. The company's stock gained 0.11% as of 3:30 p.m. ET after fluctuating between gains and losses throughout the session. This muted reaction comes as the S&P 500 gained 0.3% and the Nasdaq Composite rose 0.6%.Why? The medical technology company reported solid first-quarter results. The company also provided several key updates that investors reacted positively to.NovoCure shared important updatesA key highlight from NovoCure's earnings call was th ...

Thursday morning NovoCure (NVCR 4.28%) published its first set of quarterly results for 2025, and they pleased more than a few investors. With that tailwind, the biotech's stock price rose in excess of 4%, easily topping the slightly over 2% increase of the S&P 500 index.A double beat for the inaugural quarterFor the first quarter, NovoCure recorded net revenue that was just shy of $155 million. That was a nearly 12% improvement over the same period of 2024. Compounding that, the biotech managed to narrow i ...

NovoCure Ltd NVCR reported a first-quarter 2025 loss of 31 cents, down from the 36-cent loss reported a year ago, beating the consensus loss of 46 cents.Sales increased 12% year over year to $155 million, beating the consensus of $146.6 million.The U.S., Germany, France, and Japan contributed $93.2 million, $18.7 million, $17.9 million, and $8.7 million, respectively, while other active markets contributed $11.9 million.Revenue in Greater China from Novocure’s partnership with Zai Lab totaled $4.6 million.R ...

NovoCure (NVCR) reported $154.99 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 11.9%. EPS of -$0.31 for the same period compares to -$0.36 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $147.57 million, representing a surprise of +5.03%. The company delivered an EPS surprise of +34.04%, with the consensus EPS estimate being -$0.47.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- a ...

NovoCure Limited (NASDAQ:NVCR) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Ingrid Goldberg - IR Bill Doyle - Executive Chairman Ashley Cordova - CEO Christoph Brackmann - CFO Frank Leonard - EVP and President, NovoCure Oncology Nicolas Leupin - CMO Conference Call Participants Larry Biegelsen - Wells Fargo Jason Bednar - Piper Sandler Vijay Kumar - Evercore ISI Jessica Fye - JPMorgan Emily Bodnar - H.C. Wainwright Operator Good day, and thank you for standing by. Welcome ...

© 2025 Novocure GmbH 2 Confidential © 2024 Novocu © 2025 re GmbH Novocure GmbH 1 © 20254 Novocure GmbH GmbH 4 2024 achievements and 2025 milestones ahead | | DRIVING COMMERCIAL | ADVANCING | DELIVERING | | --- | --- | --- | --- | | | ADOPTION | CLINICAL PIPELINE | PRODUCT INNOVATION | | METIS met primary endpoint | 2024 Generated $605 million | | New array FDA approved | | PANOVA-3 met primary endpoint | ACHIEVEMENTS in net revenues | | and rolling-out globally | | LUNAR-2 and KEYNOTE D58 | NSCLC PMA approv ...

Novocure Reports First Quarter 2025 Financial Results Quarterly net revenues of $155 million, up 12% year-over-year, with 4,268 active patients on therapy as of March 31, 2025 Results from Phase 3 PANOVA-3 trial in pancreatic cancer accepted as late-breaking abstract for presentation at 2025 American Society of Clinical Oncology Annual Meeting CE Mark approval received for Optune Lua for use concurrently with immune checkpoint inhibitor or docetaxel in adult patients with metastatic NSCLC who have progresse ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCure Limited (Exact Name of Registrant as Specified in Its Cha ...

Cancer-focused biotech NovoCure (NVCR -4.07%) was the focus of a stock price target cut on Wednesday, and investors weren't particularly happy about it.They expressed their displeasure by selling out of their positions, to the point where the company's stock was down by nearly 5% in mid-afternoon trading. As such, it was doing notably worse than the S&P 500 index, which was 0.9% in the red at that point.Reaching for the scalpelThe analyst behind the reduction was Wedbush's David Nierengarten, who now believ ...

Our Purpose: To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation. ...